GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Processa Pharmaceuticals PCSA · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.95

+1.04%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Processa Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

Processa Pharmaceuticals is based in Vero Beach, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PCSA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2022, it reported revenue of $0.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
7 Oct 2013
Employees
12
Head office
601 21ST STREET, SUITE 300, VERO BEACH, FL, 32960
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Justin YorkeIndependent Chairman of the Board$93,000
  • Mr. George NgChief Executive Officer, Director, since 2023$521,033
  • Ms. Wendy GuyFounder, Chief Administrative Officer$1.0m
  • Dr. Sian BigoraChief Development Officer and Regulatory Officer, Founder$328,251
  • Mr. Russell SkibstedChief Financial Officer
  • Dr. David YoungPresident - Research and Development, Director, since 2017$305,424
  • Mr. Patrick LinChief Business and Strategy Officer, since 2017$1.0m
  • Mr. Khoso BaluchIndependent Director$93,000
  • Mr. James NealIndependent Director$93,000
  • Ms. Geraldine PannuIndependent Director$93,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Processa Pharmaceuticals Inc employs 12 full-time employees in Hanover Maryland.
  • The company focuses on developing 499 for Necrobiosis Lipoidica treatment.
  • Processa Pharmaceuticals has an IPO listing date of 7 October 2013.

Weaknesses

  • Processa Pharmaceuticals has only 12 employees in Hanover Maryland.
  • The company's product portfolio includes 499 for head and neck cancer effects.
  • Processa Pharmaceuticals is a small company with limited resources.

Opportunities

  • Processa Pharmaceuticals can expand its 499 drug development for unmet medical needs.
  • The company may grow by targeting Necrobiosis Lipoidica treatment markets.
  • Processa Pharmaceuticals can leverage its IPO listing for future funding.

Threats

  • Processa Pharmaceuticals faces competition in the Health Care sector.
  • The company's small size may limit its ability to compete effectively.
  • Processa Pharmaceuticals must navigate regulatory challenges in Pharmaceuticals.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.